TY - JOUR
T1 - Pulmonary Hypertension in Parenchymal Lung Disease
AU - Ruggiero, Rosechelle M.
AU - Bartolome, Sonja
AU - Torres, Fernando
N1 - Funding Information:
Financial disclosures: Dr Torres is on the speaker's bureau or has participated in advisory boards for Actelion Pharmaceuticals, Gilead, United Therapeutics, and Pfizer. Dr Bartolome is on the speaker's bureaus or has participated in advisory boards for Actelion Pharmaceuticals, Gilead, and United Therapeutics. Dr Torres and Dr Bartolome participate in clinical research at UT Southwestern, which is funded by Gilead, United Therapeutics, Pfizer, Novartis, Bayer, and GeNO.
Funding Information:
This work was supported by F32 training grant: NIH 5T32HL098040-01 .
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/7
Y1 - 2012/7
N2 - The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.
AB - The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.
KW - Chronic obstructive pulmonary disease
KW - Idiopathic pulmonary fibrosis
KW - Interstitial lung disease
KW - Pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=84863088716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863088716&partnerID=8YFLogxK
U2 - 10.1016/j.hfc.2012.04.010
DO - 10.1016/j.hfc.2012.04.010
M3 - Review article
C2 - 22748906
AN - SCOPUS:84863088716
VL - 8
SP - 461
EP - 474
JO - Heart Failure Clinics
JF - Heart Failure Clinics
SN - 1551-7136
IS - 3
ER -